Table 1 Composition of GMD-ISG formulations, their independent variables and observed dependent variables.

From: A PLGA-reinforced PEG in situ gel formulation for improved sustainability of hypoglycaemic activity of glimepiride in streptozotocin-induced diabetic rats

Formulation code

Independent variables

Observed values of dependent variables

X1

X2

X3

Y1

Y2

Y3

F1

25

5

15

608.0

1111.3

2787.25

F2

25

10

10

823.58

1114.11

2551.58

F3

25

10

20

412.03

806.46

2230.13

F4

30

5

10

956.57

1438.05

2570.78

F5

25

0

10

1020.24

1520.53

2498.9

F6

20

5

20

651.55

959.69

2972.38

F7

30

5

20

436.37

904.72

2517.45

F8

25

5

15

641.66

1157.96

2807.25

F9

20

10

15

647.48

1162.63

2561.7

F10

30

0

15

745.37

1203.13

2181.8

F11

20

5

10

918.22

1386.36

3039.05

F12

20

0

15

890.82

1399.3

2928.37

F13

25

0

20

466.91

919.2

2965.57

F14

30

10

15

578.7

1134.63

1803.92

F15

25

5

15

618.0

1134.63

2803.92

  1. Note: *The observed values of Y1, Y2 and Y3 represent the means of three determinations; standard deviations were < 5% of the mean and thus are omitted from the table.
  2. Abbreviations: PLGA, poly (D, L-lactide-co-glycolide); PEG, polyethylene glycol; X1, PLGA %; X2, PEG %; X3, BB % in NMP; Y1, initial amount of GMD released after 2 hours (μg); Y2, amount of GMD released after 24 hours (μg); Y3, cumulative amount of GMD released after 28 days (μg).
Back to article page